UNSPSC 51172158: Alverine citrate

This classification denotes an antispasmotic agent and anticholinergic agent with the molecular formula C20H27N.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9JFB58YK1E, chemically known as n,n-bis(3-phenylpropyl)ethylamine but more generally known as alverine citrate, which bears US NIH Compound Identifier 3678. European Medicines Agency schedules Alverine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00421MIG.

Most nations, for tariff and trade purposes, schedule alverine citrate under HS 29214980 and SITC 51454. As of Q4 2014, ALVERINE CITRATE remains US FDA's Preferred Term for this commodity. Alverine citrate bears US NLM NCI C72692. SMILES: CCN(CCCC1CCCCC1)CCCC2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51172158 Alveoline citrate is a Commodity code that encompasses pharmaceutical products and related specimen-collection and testing services procured by state and local health and corrections agencies. The recent opportunities tagged to this code reflect a broader set of pharmacy benefit and drug-testing procurement activity rather than the single active pharmaceutical ingredient named in the code title. State and local governments soliciting under this code are purchasing offender drug-screening and confirmation testing, generic multi-source pharmaceutical products for distribution through state and local facilities, and exploring direct-to-manufacturer prescription fulfillment models for state employee health plans and Medicaid programs. The issuing bodies include county corrections departments, state health and human services commissions, and multistate cooperative purchasing alliances serving state agencies and local governments across multiple states.

Recent activity spans Texas and Minnesota-led multistate purchasing. Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 on July 9, 2026, due July 23, 2026, for offender specimen collection and drug testing services covering two sites in Plano and McKinney with an estimated contract value of $600,000 over two years plus three optional one-year renewals, requiring SAMHSA, TX DPS, or CAP lab certification and per-test pricing for five-panel, six-panel, and ancillary screening with LC/MS/MS or GC/MS confirmation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, effective July 1, 2026, with price competitiveness weighted at 75 percent of evaluation. The Texas Health and Human Services Commission also posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program serving self-insured state employee and Medicaid populations, with no formal award value or timeline yet established at the information-gathering phase.